ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CHB Global X China Biotech Innovations ETF

6.64
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
Global X China Biotech Innovations ETF NASDAQ:CHB NASDAQ Exchange Traded Fund
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 6.64 2.67 10.66 0 01:00:00

Rule 8 - Chubb - Replacement

24/07/2003 12:35pm

UK Regulatory


RNS Number:9209N
Merrill Lynch Investment ManagersLd
24 July 2003


                                ** AMENDMENT **

This announcement is replacing RNS Number 8630N released on 23rd July 2003 at
10.57am. This is due to an amendment of the total holding. All changes have been
marked with an asterix.



     FORM 8.1/8.3

Lodge with Company Announcements Office (which will publicise and copy to the
Panel). Use separate form for each class of securities in which dealings have
been made.

     Date of disclosure: *24th July, 2003

DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKE-OVERS
AND MERGERS

Date of dealing: 22nd July, 2003

Dealing in:           Chubb plc          (Name of Company)

(1) Class of securities: 36p Ordinary Shares      (eg ordinary shares):

(2)

Amount bought                Amount sold                      Price per unit
                             100,000                          75.5p
                             75,000                           75.63p

(3)     Resultant total of the same class owned or controlled

        (and percentage of class * 59,563,999     * (7.18%)


(4)     Party making disclosure : MERRILL LYNCH INVESTMENT MANAGERS LIMITED


(5)     EITHER (a) Name of purchaser/vendor (note 1)

        OR     (b) If dealing for discretionary client(s), name of fund 
                   management organisation:

                   MERRILL LYNCH INVESTMENT MANAGERS LIMITED


(6)     Reason for disclosure (Note 2)

        (a) associate of (i) offeror (Note 3)     XXX/NO

                         (ii) offeree company     YES/XX


        Specify which category or categories of associate (1-8 overleaf)


        If category (8), explain............Category 6...............


        (b) Rule 8.3 (ie disclosure because of ownership or control of 1%
            or more of the class of relevant securities dealt in)     YES/XX


Signed, for and on behalf of the party named in (4) above


(Also print name of signatory): Keli Walters


Telephone and extension number 020 7964 7492



Note 1.     Specify owner, not nominee or vehicle company. If relevant,
also identify controller of owner, eg where an owner normally acts on
instructions of a controller.

Note 2.     Disclosure might be made for more than one reason: if so,
state all reasons.

Note 3.     Specify which offeror if there is more than one.

Note 4.     When an arrangement exists with any offeror, with the
offeree company or with an associate of any offeror or of the offeree
company in relation to relevant securities, details of such arrangement
must be disclosed, as required by Note 6 on Rule 8.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCPUUMPMUPWGGC

1 Year Global X China Biotech I... Chart

1 Year Global X China Biotech I... Chart

1 Month Global X China Biotech I... Chart

1 Month Global X China Biotech I... Chart

Your Recent History

Delayed Upgrade Clock